1
|
Tsai PH, Sun JR, Chien Y, Chan MS, Khor W, Yang HC, Huang CH, Hsiung CN, Hwa TY, Lin YY, Yeh CL, Wang ML, Yang YP, Chen YM, Tsai FT, Lee MS, Cheng YH, Tsai SK, Liu PC, Chou SJ, Chiou SH. Modifications of lipid pathways restrict SARS-CoV-2 propagation in human induced pluripotent stem cell-derived 3D airway organoids. J Adv Res 2024; 60:127-140. [PMID: 37557954 PMCID: PMC11156708 DOI: 10.1016/j.jare.2023.08.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2023] [Revised: 07/25/2023] [Accepted: 08/06/2023] [Indexed: 08/11/2023] Open
Abstract
BACKGROUND Modifications of lipid metabolism were closely associated with the manifestations and prognosis of coronavirus disease of 2019 (COVID-19). Pre-existing metabolic conditions exacerbated the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection while modulations of aberrant lipid metabolisms alleviated the manifestations. To elucidate the underlying mechanisms, an experimental platform that reproduces human respiratory physiology is required. METHODS Here we generated induced pluripotent stem cell-derived airway organoids (iPSC-AOs) that resemble the human native airway. Single-cell sequencing (ScRNAseq) and microscopic examination verified the cellular heterogeneity and microstructures of iPSC-AOs, respectively. We subjected iPSC-AOs to SARS-CoV-2 infection and investigated the treatment effect of lipid modifiers statin drugs on viral pathogenesis, gene expression, and the intracellular trafficking of the SARS-CoV-2 entry receptor angiotensin-converting enzyme-2 (ACE-2). RESULTS In SARS-CoV-2-infected iPSC-AOs, immunofluorescence staining detected the SARS-CoV-2 spike (S) and nucleocapsid (N) proteins and bioinformatics analysis further showed the aberrant enrichment of lipid-associated pathways. In addition, SARS-CoV-2 hijacked the host RNA replication machinery and generated the new isoforms of a high-density lipoprotein constituent apolipoprotein A1 (APOA1) and the virus-scavenging protein deleted in malignant brain tumors 1 (DMBT1). Manipulating lipid homeostasis using cholesterol-lowering drugs (e.g. Statins) relocated the viral entry receptor angiotensin-converting enzyme-2 (ACE-2) and decreased N protein expression, leading to the reduction of SARS-CoV-2 entry and replication. The same lipid modifications suppressed the entry of luciferase-expressing SARS-CoV-2 pseudoviruses containing the S proteins derived from different SARS-CoV-2 variants, i.e. wild-type, alpha, delta, and omicron. CONCLUSIONS Together, our data demonstrated that modifications of lipid pathways restrict SARS-CoV-2 propagation in the iPSC-AOs, which the inhibition is speculated through the translocation of ACE2 from the cell membrane to the cytosol. Considering the highly frequent mutation and generation of SARS-CoV-2 variants, targeting host metabolisms of cholesterol or other lipids may represent an alternative approach against SARS-CoV-2 infection.
Collapse
Affiliation(s)
- Ping-Hsing Tsai
- Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan; Institute of Pharmacology, School of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan
| | - Jun-Ren Sun
- Institute of Preventive Medicine, National Defense Medical Center, Taipei 11217, Taiwan; Graduate Institute of Medical Science, National Defense Medical Center, Taipei, Taiwan; Department of Physiology and Biophysics, Graduate Institute of Physiology, National Defense Medical Center, Taipei, Taiwan
| | - Yueh Chien
- Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan
| | - Man Sheung Chan
- Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan
| | - Winnie Khor
- Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan
| | - Hsin-Chou Yang
- Institute of Statistical Science, Academia Sinica, Taipei 11529, Taiwan
| | - Chih-Heng Huang
- Institute of Preventive Medicine, National Defense Medical Center, Taipei 11217, Taiwan; Department of Microbiology and Immunology, National Defense Medical Center, Taipei 11217, Taiwan; Graduate Institute of Medical Science, National Defense Medical Center, Taipei, Taiwan
| | - Chia-Ni Hsiung
- Institute of Statistical Science, Academia Sinica, Taipei 11529, Taiwan
| | - Teh-Yang Hwa
- Institute of Statistical Science, Academia Sinica, Taipei 11529, Taiwan
| | - Yi-Ying Lin
- Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan
| | - Chih-Ling Yeh
- Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan
| | - Mong-Lien Wang
- Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan; Institute of Food Safety and Health Risk Assessment, School of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan
| | - Yi-Ping Yang
- Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan; Institute of Food Safety and Health Risk Assessment, School of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan
| | - Yuh-Min Chen
- Department of Chest Medicine, Taipei Veterans General Hospital, Taipei 112, Taiwan; Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan
| | - Fu-Ting Tsai
- Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan
| | - Meng-Shiue Lee
- Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan
| | - Yun-Hsiang Cheng
- Institute of Preventive Medicine, National Defense Medical Center, Taipei 11217, Taiwan; Graduate Institute of Medical Science, National Defense Medical Center, Taipei, Taiwan; Department of Physiology and Biophysics, Graduate Institute of Physiology, National Defense Medical Center, Taipei, Taiwan
| | - Shan-Ko Tsai
- Institute of Preventive Medicine, National Defense Medical Center, Taipei 11217, Taiwan
| | - Ping-Cheng Liu
- Department of Microbiology and Immunology, National Defense Medical Center, Taipei 11217, Taiwan; Graduate Institute of Applied Science and Technology, National Taiwan University of Science and Technology, Taipei, Taiwan
| | - Shih-Jie Chou
- Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan; Institute of Pharmacology, School of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan.
| | - Shih-Hwa Chiou
- Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan; Institute of Pharmacology, School of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan.
| |
Collapse
|
2
|
De Meyer A, Meuleman P. Preclinical animal models to evaluate therapeutic antiviral antibodies. Antiviral Res 2024; 225:105843. [PMID: 38548022 DOI: 10.1016/j.antiviral.2024.105843] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2024] [Accepted: 02/25/2024] [Indexed: 04/05/2024]
Abstract
Despite the availability of effective preventative vaccines and potent small-molecule antiviral drugs, effective non-toxic prophylactic and therapeutic measures are still lacking for many viruses. The use of monoclonal and polyclonal antibodies in an antiviral context could fill this gap and provide effective virus-specific medical interventions. In order to develop these therapeutic antibodies, preclinical animal models are of utmost importance. Due to the variability in viral pathogenesis, immunity and overall characteristics, the most representative animal model for human viral infection differs between virus species. Therefore, throughout the years researchers sought to find the ideal preclinical animal model for each virus. The most used animal models in preclinical research include rodents (mice, ferrets, …) and non-human primates (macaques, chimpanzee, ….). Currently, antibodies are tested for antiviral efficacy against a variety of viruses including different hepatitis viruses, human immunodeficiency virus (HIV), influenza viruses, respiratory syncytial virus (RSV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and rabies virus. This review provides an overview of the current knowledge about the preclinical animal models that are used for the evaluation of therapeutic antibodies for the abovementioned viruses.
Collapse
Affiliation(s)
- Amse De Meyer
- Laboratory of Liver Infectious Diseases, Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium
| | - Philip Meuleman
- Laboratory of Liver Infectious Diseases, Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
| |
Collapse
|
3
|
Kamensek U, Cemazar M, Kranjc Brezar S, Jesenko T, Kos S, Znidar K, Markelc B, Modic Z, Komel T, Gorse T, Rebersek E, Jakopic H, Sersa G. What We Learned about the Feasibility of Gene Electrotransfer for Vaccination on a Model of COVID-19 Vaccine. Pharmaceutics 2023; 15:1981. [PMID: 37514166 PMCID: PMC10385748 DOI: 10.3390/pharmaceutics15071981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2023] [Revised: 07/14/2023] [Accepted: 07/18/2023] [Indexed: 07/30/2023] Open
Abstract
DNA vaccination is one of the emerging approaches for a wide range of applications, including prophylactic vaccination against infectious diseases and therapeutic vaccination against cancer. The aim of this study was to evaluate the feasibility of our previously optimized protocols for gene electrotransfer (GET)-mediated delivery of plasmid DNA into skin and muscle tissues on a model of COVID-19 vaccine. Plasmids encoding the SARS-CoV-2 proteins spike (S) and nucleocapsid (N) were used as the antigen source, and a plasmid encoding interleukin 12 (IL-12) was used as an adjuvant. Vaccination was performed in the skin or muscle tissue of C57BL/6J mice on days 0 and 14 (boost). Two weeks after the boost, blood, spleen, and transfected tissues were collected to determine the expression of S, N, IL-12, serum interferon-γ, the induction of antigen-specific IgG antibodies, and cytotoxic T-cells. In accordance with prior in vitro experiments that indicated problems with proper expression of the S protein, vaccination with S did not induce S-specific antibodies, whereas significant induction of N-specific antibodies was detected after vaccination with N. Intramuscular vaccination outperformed skin vaccination and resulted in significant induction of humoral and cell-mediated immunity. Moreover, both boost and adjuvant were found to be redundant for the induction of an immune response. Overall, the study confirmed the feasibility of the GET for DNA vaccination and provided valuable insights into this approach.
Collapse
Affiliation(s)
- Urska Kamensek
- Institute of Oncology Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, Slovenia
- Biotechnical Faculty, University of Ljubljana, Jamnikarjeva Ulica 101, SI-1000 Ljubljana, Slovenia
| | - Maja Cemazar
- Institute of Oncology Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, Slovenia
- Faculty of Health Sciences, University of Primorska, Polje 42, SI-6310 Izola, Slovenia
| | | | - Tanja Jesenko
- Institute of Oncology Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, Slovenia
- Faculty of Medicine, University of Ljubljana, Vrazov Trg 2, SI-1000 Ljubljana, Slovenia
| | - Spela Kos
- Institute of Oncology Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, Slovenia
| | - Katarina Znidar
- Institute of Oncology Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, Slovenia
| | - Bostjan Markelc
- Institute of Oncology Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, Slovenia
- Faculty of Health Sciences, University of Ljubljana, Zdravstvena Pot 5, SI-1000 Ljubljana, Slovenia
| | - Ziva Modic
- Institute of Oncology Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, Slovenia
- Faculty of Medicine, University of Ljubljana, Vrazov Trg 2, SI-1000 Ljubljana, Slovenia
| | - Tilen Komel
- Institute of Oncology Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, Slovenia
- Faculty of Medicine, University of Ljubljana, Vrazov Trg 2, SI-1000 Ljubljana, Slovenia
| | - Tim Gorse
- Biotechnical Faculty, University of Ljubljana, Jamnikarjeva Ulica 101, SI-1000 Ljubljana, Slovenia
| | - Eva Rebersek
- Biotechnical Faculty, University of Ljubljana, Jamnikarjeva Ulica 101, SI-1000 Ljubljana, Slovenia
| | - Helena Jakopic
- Biotechnical Faculty, University of Ljubljana, Jamnikarjeva Ulica 101, SI-1000 Ljubljana, Slovenia
| | - Gregor Sersa
- Institute of Oncology Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, Slovenia
- Faculty of Health Sciences, University of Ljubljana, Zdravstvena Pot 5, SI-1000 Ljubljana, Slovenia
| |
Collapse
|
4
|
Wouters E, Verbrugghe C, Abdelnabi R, Devloo R, De Clippel D, Jochmans D, De Bleser D, Weynand B, Compernolle V, Neyts J, Feys HB. Intranasal administration of convalescent plasma protects against SARS-CoV-2 infection in hamsters. EBioMedicine 2023; 92:104597. [PMID: 37148586 PMCID: PMC10171892 DOI: 10.1016/j.ebiom.2023.104597] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2023] [Revised: 04/18/2023] [Accepted: 04/18/2023] [Indexed: 05/08/2023] Open
Abstract
BACKGROUND Convalescent plasma (CP) transfusion is an early option for treating infections with pandemic potential, often preceding vaccine or antiviral drug rollout. Heterogenous findings from randomized clinical trials on transfusion of COVID-19 CP (CCP) have been reported. However, meta-analysis suggests that transfusion of high titer CCP is associated with a mortality benefit for COVID-19 outpatients or inpatients treated within 5 days after symptom onset, indicating the importance of early administration. METHODS We tested if CCP is an effective prophylactic against SARS-CoV-2 infection by the intranasal administration of 25 μL CCP/nostril (i.e. 0.01-0.06 mg anti-RBD antibodies/kg) in hamsters exposed to infected littermates. FINDINGS In this model, 40% of CCP treated hamsters were fully protected and 40% had significantly reduced viral loads, the remaining 20% was not protected. The effect seems dose-dependent because high-titer CCP from a vaccinated donor was more effective than low-titer CCP from a donation prior to vaccine rollout. Intranasal administration of human CCP resulted in a reactive (immune) response in hamster lungs, however this was not observed upon administration of hamster CCP. INTERPRETATION We conclude that CCP is an effective prophylactic when used directly at the site of primary infection. This option should be considered in future prepandemic preparedness plans. FUNDING Flanders Innovation & Entrepreneurship (VLAIO) and the Foundation for Scientific Research of the Belgian Red Cross Flanders.
Collapse
Affiliation(s)
- Elise Wouters
- Transfusion Research Center, Belgian Red Cross-Flanders, Ghent, Belgium
| | - Caro Verbrugghe
- Transfusion Research Center, Belgian Red Cross-Flanders, Ghent, Belgium; Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium
| | - Rana Abdelnabi
- KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000, Leuven, Belgium
| | - Rosalie Devloo
- Transfusion Research Center, Belgian Red Cross-Flanders, Ghent, Belgium
| | | | - Dirk Jochmans
- KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000, Leuven, Belgium
| | | | - Birgit Weynand
- KU Leuven Department of Imaging and Pathology, Translational Cell and Tissue Research, Division of Translational Cell and Tissue Research, B-3000, Leuven, Belgium
| | - Veerle Compernolle
- Transfusion Research Center, Belgian Red Cross-Flanders, Ghent, Belgium; Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium; Blood Services of the Belgian Red Cross-Flanders, Mechelen, Belgium; Transfusion Innovation Center, Belgian Red Cross-Flanders, Ghent, Belgium
| | - Johan Neyts
- KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000, Leuven, Belgium
| | - Hendrik B Feys
- Transfusion Research Center, Belgian Red Cross-Flanders, Ghent, Belgium; Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium; Blood Services of the Belgian Red Cross-Flanders, Mechelen, Belgium.
| |
Collapse
|
5
|
Cuypers ML, Geukens N, Hollevoet K, Declerck P, Dewilde M. Exploring the Fate of Antibody-Encoding pDNA after Intramuscular Electroporation in Mice. Pharmaceutics 2023; 15:pharmaceutics15041160. [PMID: 37111645 PMCID: PMC10146361 DOI: 10.3390/pharmaceutics15041160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2023] [Revised: 03/29/2023] [Accepted: 03/31/2023] [Indexed: 04/29/2023] Open
Abstract
DNA-based antibody therapy seeks to administer the encoding nucleotide sequence rather than the antibody protein. To further improve the in vivo monoclonal antibody (mAb) expression, a better understanding of what happens after the administration of the encoding plasmid DNA (pDNA) is required. This study reports the quantitative evaluation and localization of the administered pDNA over time and its association with corresponding mRNA levels and systemic protein concentrations. pDNA encoding the murine anti-HER2 4D5 mAb was administered to BALB/c mice via intramuscular injection followed by electroporation. Muscle biopsies and blood samples were taken at different time points (up to 3 months). In muscle, pDNA levels decreased 90% between 24 h and one week post treatment (p < 0.0001). In contrast, mRNA levels remained stable over time. The 4D5 antibody plasma concentrations reached peak levels at week two followed by a slow decrease (50% after 12 weeks, p < 0.0001). Evaluation of pDNA localization revealed that extranuclear pDNA was cleared fast, whereas the nuclear fraction remained relatively stable. This is in line with the observed mRNA and protein levels over time and indicates that only a minor fraction of the administered pDNA is ultimately responsible for the observed systemic mAb levels. In conclusion, this study demonstrates that durable expression is dependent on the nuclear uptake of the pDNA. Therefore, efforts to increase the protein levels upon pDNA-based gene therapy should focus on strategies to increase both cellular entry and migration of the pDNA into the nucleus. The currently applied methodology can be used to guide the design and evaluation of novel plasmid-based vectors or alternative delivery methods in order to achieve a robust and prolonged protein expression.
Collapse
Affiliation(s)
- Marie-Lynn Cuypers
- Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven-University of Leuven, O&N II Herestraat 49 Box 820, 3000 Leuven, Belgium
| | - Nick Geukens
- PharmAbs-The KU Leuven Antibody Center, KU Leuven-University of Leuven, O&N II Herestraat 49 Box 820, 3000 Leuven, Belgium
| | - Kevin Hollevoet
- PharmAbs-The KU Leuven Antibody Center, KU Leuven-University of Leuven, O&N II Herestraat 49 Box 820, 3000 Leuven, Belgium
| | - Paul Declerck
- Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven-University of Leuven, O&N II Herestraat 49 Box 820, 3000 Leuven, Belgium
- PharmAbs-The KU Leuven Antibody Center, KU Leuven-University of Leuven, O&N II Herestraat 49 Box 820, 3000 Leuven, Belgium
| | - Maarten Dewilde
- Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven-University of Leuven, O&N II Herestraat 49 Box 820, 3000 Leuven, Belgium
- PharmAbs-The KU Leuven Antibody Center, KU Leuven-University of Leuven, O&N II Herestraat 49 Box 820, 3000 Leuven, Belgium
| |
Collapse
|
6
|
Breukers J, Ven K, Struyfs C, Ampofo L, Rutten I, Imbrechts M, Pollet F, Van Lent J, Kerstens W, Noppen S, Schols D, De Munter P, Thibaut HJ, Vanhoorelbeke K, Spasic D, Declerck P, Cammue BPA, Geukens N, Thevissen K, Lammertyn J. FLUIDOT: A Modular Microfluidic Platform for Single-Cell Study and Retrieval, with Applications in Drug Tolerance Screening and Antibody Mining. SMALL METHODS 2023; 7:e2201477. [PMID: 36642827 DOI: 10.1002/smtd.202201477] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/11/2022] [Revised: 12/21/2022] [Indexed: 06/17/2023]
Abstract
Advancements in lab-on-a-chip technologies have revolutionized the single-cell analysis field. However, an accessible platform for in-depth screening and specific retrieval of single cells, which moreover enables studying diverse cell types and performing various downstream analyses, is still lacking. As a solution, FLUIDOT is introduced, a versatile microfluidic platform incorporating customizable microwells, optical tweezers and an interchangeable cell-retrieval system. Thanks to its smart microfluidic design, FLUIDOT is straightforward to fabricate and operate, rendering the technology widely accessible. The performance of FLUIDOT is validated and its versatility is subsequently demonstrated in two applications. First, drug tolerance in yeast cells is studied, resulting in the discovery of two treatment-tolerant populations. Second, B cells from convalescent COVID-19 patients are screened, leading to the discovery of highly affine, in vitro neutralizing monoclonal antibodies against SARS-CoV-2. Owing to its performance, flexibility, and accessibility, it is foreseen that FLUIDOT will enable phenotypic and genotypic analysis of diverse cell samples and thus elucidate unexplored biological questions.
Collapse
Affiliation(s)
- Jolien Breukers
- Department of Biosystems, Biosensors group, KU Leuven, Willem de Croylaan 42, Leuven, 3001, Belgium
- LISCO, KU Leuven Institute for Single Cell Omics, ON4 Herestraat 49, Leuven, 3000, Belgium
| | - Karen Ven
- Department of Biosystems, Biosensors group, KU Leuven, Willem de Croylaan 42, Leuven, 3001, Belgium
- LISCO, KU Leuven Institute for Single Cell Omics, ON4 Herestraat 49, Leuven, 3000, Belgium
- MabMine: KU Leuven Single B Cell Mining Platform, KU Leuven, ON2 Herestraat 49, 3000, Leuven, Belgium
| | - Caroline Struyfs
- Centre of Microbial and Plant Genetics, KU Leuven, Kasteelpark Arenberg 20, Leuven, 3001, Belgium
| | - Louanne Ampofo
- Department of Biosystems, Biosensors group, KU Leuven, Willem de Croylaan 42, Leuven, 3001, Belgium
- MabMine: KU Leuven Single B Cell Mining Platform, KU Leuven, ON2 Herestraat 49, 3000, Leuven, Belgium
- PharmAbs, The KU Leuven Antibody Center, KU Leuven, ON 2 Herestraat 49, Leuven, 3000, Belgium
- Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven, ON2 Herestraat 49, Leuven, 3000, Belgium
| | - Iene Rutten
- Department of Biosystems, Biosensors group, KU Leuven, Willem de Croylaan 42, Leuven, 3001, Belgium
- LISCO, KU Leuven Institute for Single Cell Omics, ON4 Herestraat 49, Leuven, 3000, Belgium
| | - Maya Imbrechts
- MabMine: KU Leuven Single B Cell Mining Platform, KU Leuven, ON2 Herestraat 49, 3000, Leuven, Belgium
- PharmAbs, The KU Leuven Antibody Center, KU Leuven, ON 2 Herestraat 49, Leuven, 3000, Belgium
- Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven, ON2 Herestraat 49, Leuven, 3000, Belgium
| | - Francesca Pollet
- Department of Biosystems, Biosensors group, KU Leuven, Willem de Croylaan 42, Leuven, 3001, Belgium
| | - Julie Van Lent
- Department of Biosystems, Biosensors group, KU Leuven, Willem de Croylaan 42, Leuven, 3001, Belgium
| | - Winnie Kerstens
- Translational Platform Virology and Chemotherapy, Rega Institute, KU Leuven, Rega - Herestraat 49, Leuven, 3000, Belgium
| | - Sam Noppen
- Laboratory of Virology and Chemotherapy, Rega Institute, KU Leuven, Rega - Herestraat 49, Leuven, 3000, Belgium
| | - Dominique Schols
- Laboratory of Virology and Chemotherapy, Rega Institute, KU Leuven, Rega - Herestraat 49, Leuven, 3000, Belgium
| | - Paul De Munter
- Department of Internal Medicine, University Hospitals Leuven, UZ Herestraat 49, Leuven, 3000, Belgium
- Laboratory for Clinical Infectious and Inflammatory Disorders, KU Leuven, UZ Herestraat 49, Leuven, 3000, Belgium
| | - Hendrik Jan Thibaut
- Translational Platform Virology and Chemotherapy, Rega Institute, KU Leuven, Rega - Herestraat 49, Leuven, 3000, Belgium
| | - Karen Vanhoorelbeke
- MabMine: KU Leuven Single B Cell Mining Platform, KU Leuven, ON2 Herestraat 49, 3000, Leuven, Belgium
- PharmAbs, The KU Leuven Antibody Center, KU Leuven, ON 2 Herestraat 49, Leuven, 3000, Belgium
- Laboratory for Thrombosis Research, KU Leuven Campus Kulak Kortrijk, Etienne Sabbelaan 53, Kortrijk, 8500, Belgium
| | - Dragana Spasic
- Department of Biosystems, Biosensors group, KU Leuven, Willem de Croylaan 42, Leuven, 3001, Belgium
| | - Paul Declerck
- MabMine: KU Leuven Single B Cell Mining Platform, KU Leuven, ON2 Herestraat 49, 3000, Leuven, Belgium
- PharmAbs, The KU Leuven Antibody Center, KU Leuven, ON 2 Herestraat 49, Leuven, 3000, Belgium
- Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven, ON2 Herestraat 49, Leuven, 3000, Belgium
| | - Bruno P A Cammue
- Centre of Microbial and Plant Genetics, KU Leuven, Kasteelpark Arenberg 20, Leuven, 3001, Belgium
| | - Nick Geukens
- MabMine: KU Leuven Single B Cell Mining Platform, KU Leuven, ON2 Herestraat 49, 3000, Leuven, Belgium
- PharmAbs, The KU Leuven Antibody Center, KU Leuven, ON 2 Herestraat 49, Leuven, 3000, Belgium
- Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven, ON2 Herestraat 49, Leuven, 3000, Belgium
| | - Karin Thevissen
- Centre of Microbial and Plant Genetics, KU Leuven, Kasteelpark Arenberg 20, Leuven, 3001, Belgium
| | - Jeroen Lammertyn
- Department of Biosystems, Biosensors group, KU Leuven, Willem de Croylaan 42, Leuven, 3001, Belgium
- LISCO, KU Leuven Institute for Single Cell Omics, ON4 Herestraat 49, Leuven, 3000, Belgium
- MabMine: KU Leuven Single B Cell Mining Platform, KU Leuven, ON2 Herestraat 49, 3000, Leuven, Belgium
- LIMNI, KU Leuven Institute for Micro- and Nanoscale Integration, Celestijnenlaan 200F, Leuven, 3001, Belgium
| |
Collapse
|
7
|
Callaway HM, Hastie KM, Schendel SL, Li H, Yu X, Shek J, Buck T, Hui S, Bedinger D, Troup C, Dennison SM, Li K, Alpert MD, Bailey CC, Benzeno S, Bonnevier JL, Chen JQ, Chen C, Cho H, Crompton PD, Dussupt V, Entzminger KC, Ezzyat Y, Fleming JK, Geukens N, Gilbert AE, Guan Y, Han X, Harvey CJ, Hatler JM, Howie B, Hu C, Huang A, Imbrechts M, Jin A, Kamachi N, Keitany G, Klinger M, Kolls JK, Krebs SJ, Li T, Luo F, Maruyama T, Meehl MA, Mendez-Rivera L, Musa A, Okumura CJ, Rubin BER, Sato AK, Shen M, Singh A, Song S, Tan J, Trimarchi JM, Upadhyay DP, Wang Y, Yu L, Yuan TZ, Yusko E, Peters B, Tomaras G, Saphire EO. Bivalent intra-spike binding provides durability against emergent Omicron lineages: Results from a global consortium. Cell Rep 2023; 42:112014. [PMID: 36681898 PMCID: PMC9834171 DOI: 10.1016/j.celrep.2023.112014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2022] [Revised: 11/25/2022] [Accepted: 01/05/2023] [Indexed: 01/14/2023] Open
Abstract
The SARS-CoV-2 Omicron variant of concern (VoC) and its sublineages contain 31-36 mutations in spike and escape neutralization by most therapeutic antibodies. In a pseudovirus neutralization assay, 66 of the nearly 400 candidate therapeutics in the Coronavirus Immunotherapeutic Consortium (CoVIC) panel neutralize Omicron and multiple Omicron sublineages. Among natural immunoglobulin Gs (IgGs), especially those in the receptor-binding domain (RBD)-2 epitope community, nearly all Omicron neutralizers recognize spike bivalently, with both antigen-binding fragments (Fabs) simultaneously engaging adjacent RBDs on the same spike. Most IgGs that do not neutralize Omicron bind either entirely monovalently or have some (22%-50%) monovalent occupancy. Cleavage of bivalent-binding IgGs to Fabs abolishes neutralization and binding affinity, with disproportionate loss of activity against Omicron pseudovirus and spike. These results suggest that VoC-resistant antibodies overcome mutagenic substitution via avidity. Hence, vaccine strategies targeting future SARS-CoV-2 variants should consider epitope display with spacing and organization identical to trimeric spike.
Collapse
Affiliation(s)
- Heather M Callaway
- Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA
| | - Kathryn M Hastie
- Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA
| | - Sharon L Schendel
- Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA
| | - Haoyang Li
- Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA
| | - Xiaoying Yu
- Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA
| | - Jeremy Shek
- Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA
| | - Tierra Buck
- Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA
| | - Sean Hui
- Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA
| | - Dan Bedinger
- Carterra, 825 N. 300 W. Ste. C309, Salt Lake City, UT 84103, USA
| | - Camille Troup
- Carterra, 825 N. 300 W. Ste. C309, Salt Lake City, UT 84103, USA
| | - S Moses Dennison
- Center for Human Systems Immunology, Departments of Surgery, Immunology, and Molecular Genetics and Microbiology and Duke Human Vaccine Institute, Duke University, Durham, NC 27701, USA
| | - Kan Li
- Center for Human Systems Immunology, Departments of Surgery, Immunology, and Molecular Genetics and Microbiology and Duke Human Vaccine Institute, Duke University, Durham, NC 27701, USA
| | | | | | - Sharon Benzeno
- Adaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA 98102, USA
| | | | - Jin-Qiu Chen
- ACRO Biosystems, 1 Innovation Way, Newark, DE 19711, USA
| | - Charm Chen
- ACRO Biosystems, 1 Innovation Way, Newark, DE 19711, USA
| | - Hyeseon Cho
- Antibody Biology Unit, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA; Malaria Infection Biology and Immunity Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
| | - Peter D Crompton
- Antibody Biology Unit, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA; Malaria Infection Biology and Immunity Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
| | - Vincent Dussupt
- Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA
| | - Kevin C Entzminger
- Abwiz Bio, Inc., 9823 Pacific Heights Blvd. Suite J, San Diego, CA 92121, USA
| | - Yassine Ezzyat
- Jounce Therapeutics, Inc., 780 Memorial Drive, Cambridge, MA 02139, USA
| | - Jonathan K Fleming
- Abwiz Bio, Inc., 9823 Pacific Heights Blvd. Suite J, San Diego, CA 92121, USA
| | - Nick Geukens
- PharmAbs, The KU Leuven Antibody Center, KU Leuven, 3000 Leuven, Belgium
| | - Amy E Gilbert
- Adaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA 98102, USA
| | - Yongjun Guan
- Antibody BioPharm, Inc., 401 Professional Dr Ste 241, Gaithersburg, MD 20879, USA; Shanghai Life Technology Co., Ltd., 781 Cai Lun Rd, Ste 801, Pudong, Shanghai 201203, China
| | - Xiaojian Han
- Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing 400010, China
| | - Christopher J Harvey
- Jounce Therapeutics, Inc., 780 Memorial Drive, Cambridge, MA 02139, USA; Phenomic AI, 661 University Avenue, Suite 1300 MaRS Centre, West Tower, Toronto, ON M5G 0B7, Canada
| | - Julia M Hatler
- Bio-techne, 614 McKinley Place NE, Minneapolis, MN 55413, USA
| | - Bryan Howie
- Adaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA 98102, USA
| | - Chao Hu
- Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing 400010, China
| | - Ailong Huang
- Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China
| | - Maya Imbrechts
- PharmAbs, The KU Leuven Antibody Center, KU Leuven, 3000 Leuven, Belgium
| | - Aishun Jin
- Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing 400010, China
| | - Nik Kamachi
- ACRO Biosystems, 1 Innovation Way, Newark, DE 19711, USA
| | - Gladys Keitany
- Adaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA 98102, USA
| | - Mark Klinger
- Adaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA 98102, USA
| | - Jay K Kolls
- Tulane School of Medicine, Center for Translational Research in Infection and Inflammation, New Orleans, LA 70112, USA
| | - Shelly J Krebs
- Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA
| | - Tingting Li
- Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing 400010, China
| | - Feiyan Luo
- Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing 400010, China
| | - Toshiaki Maruyama
- Abwiz Bio, Inc., 9823 Pacific Heights Blvd. Suite J, San Diego, CA 92121, USA
| | - Michael A Meehl
- Jounce Therapeutics, Inc., 780 Memorial Drive, Cambridge, MA 02139, USA
| | - Letzibeth Mendez-Rivera
- Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA
| | - Andrea Musa
- Adaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA 98102, USA
| | - C J Okumura
- Abwiz Bio, Inc., 9823 Pacific Heights Blvd. Suite J, San Diego, CA 92121, USA
| | - Benjamin E R Rubin
- Adaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA 98102, USA
| | - Aaron K Sato
- Twist Bioscience, 681 Gateway Blvd., South San Francisco, CA 94080, USA
| | - Meiying Shen
- Department of Endocrine Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China
| | - Anirudh Singh
- Jounce Therapeutics, Inc., 780 Memorial Drive, Cambridge, MA 02139, USA
| | - Shuyi Song
- Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing 400010, China
| | - Joshua Tan
- Antibody Biology Unit, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
| | - Jeffrey M Trimarchi
- Emmune, Inc., 14155 US Highway 1, Juno Beach, FL 33408, USA; Department of Biological Sciences, Lehigh University, 111 Research Drive, Bethlehem, PA 18015, USA
| | - Dhruvkumar P Upadhyay
- Jounce Therapeutics, Inc., 780 Memorial Drive, Cambridge, MA 02139, USA; Amgen, Inc., 360 Binney St., Cambridge, MA 02141, USA
| | - Yingming Wang
- Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing 400010, China
| | - Lei Yu
- Guangzhou Eighth People's Hospital & Guangzhou Medical University, Guangzhou 510060, China
| | - Tom Z Yuan
- Twist Bioscience, 681 Gateway Blvd., South San Francisco, CA 94080, USA
| | - Erik Yusko
- Adaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA 98102, USA
| | - Bjoern Peters
- Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA; Department of Medicine, University of California San Diego, La Jolla, CA 92039, USA
| | - Georgia Tomaras
- Center for Human Systems Immunology, Departments of Surgery, Immunology, and Molecular Genetics and Microbiology and Duke Human Vaccine Institute, Duke University, Durham, NC 27701, USA
| | - Erica Ollmann Saphire
- Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA; Department of Medicine, University of California San Diego, La Jolla, CA 92039, USA.
| |
Collapse
|
8
|
Hollevoet K, Thomas D, Compernolle G, Vermeire G, De Smidt E, De Vleeschauwer S, Smith TRF, Fisher PD, Dewilde M, Geukens N, Declerck P. Clinically relevant dosing and pharmacokinetics of DNA-encoded antibody therapeutics in a sheep model. Front Oncol 2022; 12:1017612. [PMID: 36263202 PMCID: PMC9574358 DOI: 10.3389/fonc.2022.1017612] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2022] [Accepted: 09/14/2022] [Indexed: 11/18/2022] Open
Abstract
DNA-encoded delivery and in vivo expression of antibody therapeutics presents an innovative alternative to conventional protein production and administration, including for cancer treatment. To support clinical translation, we evaluated this approach in 18 40-45 kg sheep, using a clinical-matched intramuscular electroporation (IM EP) and hyaluronidase-plasmid DNA (pDNA) coformulation setup. Two cohorts of eight sheep received either 1 or 4 mg pDNA encoding an ovine anti-cancer embryonic antigen (CEA) monoclonal antibody (mAb; OVAC). Results showed a dose-response with average maximum serum concentrations of respectively 0.3 and 0.7 µg/ml OVAC, 4-6 weeks after IM EP. OVAC was detected in all 16 sheep throughout the 6-week follow-up, and no anti-OVAC antibodies were observed. Another, more exploratory, cohort of two sheep received a 12 mg pOVAC dose. Both animals displayed a similar dose-dependent mAb increase and expression profile in the first two weeks. However, in one animal, an anti-OVAC antibody response led to loss of mAb detection four weeks after IM EP. In the other animal, no anti-drug antibodies were observed. Serum OVAC concentrations peaked at 4.9 µg/ml 6 weeks after IM EP, after which levels gradually decreased but remained detectable around 0.2 to 0.3 µg/ml throughout a 13-month follow-up. In conclusion, using a delivery protocol that is currently employed in clinical Phase 1 studies of DNA-based antibodies, we achieved robust and prolonged in vivo production of anti-cancer DNA-encoded antibody therapeutics in sheep. The learnings from this large-animal model regarding the impact of pDNA dose and host immune response on the expressed mAb pharmacokinetics can contribute to advancing clinical translation.
Collapse
Affiliation(s)
- Kevin Hollevoet
- PharmAbs, The KU Leuven Antibody Center – University of Leuven, Leuven, Belgium
- Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven – University of Leuven, Leuven, Belgium
- *Correspondence: Kevin Hollevoet,
| | - Debby Thomas
- PharmAbs, The KU Leuven Antibody Center – University of Leuven, Leuven, Belgium
- Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven – University of Leuven, Leuven, Belgium
| | - Griet Compernolle
- PharmAbs, The KU Leuven Antibody Center – University of Leuven, Leuven, Belgium
- Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven – University of Leuven, Leuven, Belgium
| | - Giles Vermeire
- Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven – University of Leuven, Leuven, Belgium
| | - Elien De Smidt
- PharmAbs, The KU Leuven Antibody Center – University of Leuven, Leuven, Belgium
- Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven – University of Leuven, Leuven, Belgium
| | | | | | | | - Maarten Dewilde
- PharmAbs, The KU Leuven Antibody Center – University of Leuven, Leuven, Belgium
- Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven – University of Leuven, Leuven, Belgium
| | - Nick Geukens
- PharmAbs, The KU Leuven Antibody Center – University of Leuven, Leuven, Belgium
| | - Paul Declerck
- PharmAbs, The KU Leuven Antibody Center – University of Leuven, Leuven, Belgium
- Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven – University of Leuven, Leuven, Belgium
| |
Collapse
|